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Background: The main objective of the present work was to compare the effects of the gonadotropin-releasing
hormone agonist (GnRH-a) and GnRH antagonist (GnRH-ant) on the gene expression profiles of oocytes obtained
from Iranian infertile couples undergoing in vitro fertilization (IVF).
Methods: Fifty infertile couples who underwent IVF between June 2012 and November 2013 at the Infertility
Center of Tehran Women General Hospital, Tehran University of Medical Sciences, were included in this study. We
included women that had undergone IVF treatment because of male factor, tubal factor, or unexplained infertility.
The women randomly underwent controlled ovarian stimulation (COS) with either the GnRH-a (n = 26) or the
GnRH-ant (n = 24). We obtained 50 germinal vesicle (GV) oocytes donated by women in each group. After the
sampling, pool of 50 GV oocytes for each group was separately analyzed by quantitative polymerase chain
reaction (qPCR).
Result: The expression levels of Adenosine triphosphatase 6 (ATPase 6), Bone morphogenetic protein 15 (BMP15), and
Neuronal apoptosis inhibitory protein (NAIP) genes were significantly upregulated in the GnRH-ant group compared to
the GnRH-a group, with the fold change of 3.990 (SD ± 1.325), 6.274 (SD ± 1.542), and 2.156 (SD ± 1.443), respectively,
(P < 0.001). Growth differentiation factor 9 (GDF9) mRNA did not have any expression in the GnRH-a group; however,
GDF9 mRNA was expressed in the GnRH-ant group. Finally, it was found that the genes involved in the DNA repairing
and cell cycle checkpoint did not have any expression in either group.
Conclusion: The present study showed, for the first time, the expression levels of genes involved in the cytoplasmic
maturity (BMP15, GDF9), adenosine triphosphate production (ATPase 6), and antiapoptotic process (NAIP), in human GV
oocytes were significantly higher in the GnRH-anta group than in the GnRH-a group in COS. Higher expression level of
these genes when GnRH-ant protocol is applied, this protocol seems to be a more appropriate choice for women with
poly cystic ovarian syndrome, because it can probably improve the expression of the aforementioned genes.
Trial registration: Current Controlled Trials: IRCT 2014031112307 N3.
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Controlled ovarian stimulation (COS) is an important part
of reproductive medicine; it also plays a vital role in indu-
cing a pregnancy through assisted reproductive technol-
ogy (ART). Higher pregnancy and implantation rates,
compared to natural cycles, can be achieved using COS.
Currently, three objectives are commonly followed when
using COS for ART: ovulation induction, suppression of
hypophyseal activity, and the growth stimulation of mul-
tiple follicles. For this purpose, two kinds of drugs are
commonly used: gonadotropin releasing hormone ago-
nists (GnRH-a) and gonadotropin releasing hormone
antagonists (GnRH-ant). Multi-follicular recruitment
causes a rapid increase in serum 17-beta estradiol (E2)
levels during stimulated cycles, which in turn results in
an untimely release of LH. The use of GnRH analogs
can prevent the luteinizing hormone (LH) surge, which
in turn improves the oocyte yield with more embryos
and allows for better selection and therefore an in-
creased pregnancy rate [1].
GnRH-a have been the most widely used drug for
women undergoing COS, either for ICSI or for IVF [2].
GnRH-ant, on the other hand, has been introduced in
clinical practice as a valid alternative in the last decade.
In contrast to GnRH-a that decrease the number of re-
ceptors, GnRH-ant competitively inhibit endogenous
GnRH from binding to its receptors. Consequently,
they induce a direct, dose-dependent block of GnRH-
receptors that are quickly reversible, which help avoid
a flare effect [1].
Since 2001, several studies have compared the efficacy
of the two GnRH analogs [2,3]. A recent Cochrane re-
view indicated no evidence of a statistically significant
difference in the rates of live births or ongoing pregnan-
cies of the two GnRH analogs. In addition, the inci-
dence of ovarian hyperstimulation syndrome (OHSS)
in GnRH-ant treatment was lower than that of the
GnRH-a treatment [3-5]. Furthermore, the following
characteristics of the two protocols have also been
compared: the number of oocytes retrieved and em-
bryos transferred, the quality of oocyte morphology,
implantation rate, the cycle cancellation rate, endomet-
rial receptivity, follicular microenvironment, the percent-
age of granulosa cells with positive DNA fragmentation
and apoptosis, genes expression in cumulus cells, and the
distribution pattern and activity of human mature oocyte
mitochondria [6-9].
It should be noted that the quality of oocytes obtained
following controlled ovarian stimulation (COS) may vary
significantly. Most oocytes are capable of being fertilized;
however, nearly half of the fertilized ones can complete
preimplantation development and even fewer ones can
still implant. It has been shown that defects or variations
in the ovulation or maturation processes have significantassociations with gene expression alterations in oocytes
and their supporting cells [10].
As mentioned earlier, although different clinical and
molecular studies have been conducted to compare the
efficacy of GnRH-a and GnRH-ant in assistant repro-
ductive technique (ATR), results have been mostly in-
consistent; Microarray studies conducted on human
oocytes have indicated that some genes are expressed in
both GV and MII stages, though with different levels. In
fact, the more the oocytes move towards the maturity,
the expression level of these genes increases [10-28].
These genes include those involved in the maturity of
human oocytes (BMP15 and GDF9, both from the TGF
beta category) [29,30], those involved in the cellular
cycle and meiosis (BUB1, MAD2L1, CDC20, ATR, and
ATM) [10-28,31], the energy-producing, mitochondrial
gene (ATPase6) [27], and NAIP, which indicates oocytes
viability [32-34]. Additionally, it is reported that COS
can affect the gene expression level of oocytes [10]. Dur-
ing ovulation, mature and immature oocytes are ob-
tained at the same time; however, the mature oocyte is
used to treat patients. If differences are observed in the
expression levels of the above mentioned genes in the
cytoplasm of the GV oocytes due to different COS pro-
tocols (i.e. GnRH-ant or GnRH-a), the same conditions
are expected to exist in the cytoplasm of mature oocytes.
In other words, if increased levels of cytoplasmic matur-
ity factors are observed following a COS protocol com-
pared to the other, it highly likely to observe the same
conditions in the cytoplasm of mature oocytes (MII)
which co-exist with the GV oocytes in the same cycle.
Therefore, for the first time, we decided to investigate the
expression levels of nine genes involved in the cytoplasmic
maturity, antiapoptotic process, cell cycle checkpoint,
DNA repairing, and adenosine triphosphate production in
germinal vesicle oocytes regarding the type of controlled
ovarian stimulation in human. No studies have so far
compared the genes expression in oocytes of women




Fifty infertile couples who underwent IVF/intracytoplasmic
sperm injection (ICSI) between June 2012 and November
2013 at the Infertility Center of Tehran Women General
Hospital, Tehran University of Medical Sciences, were in-
cluded in this study. They were in good physical and
mental conditions. We included the women that had
undergone IVF treatment because of male factor, tubal
factor, or unexplained infertility. These women did not
have ovulatory dysfunction, were aged ≤40 years, and
had a normal baseline follicle stimulating hormone
(FSH) and luteinizing hormone (LH) (<10 mIU/mL).
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Ovarian Stimulation and Oocyte Collection
The women underwent controlled ovarian stimulation
with either the GnRH-a long protocol (n = 26) or the
GnRH-ant fixed multi-dose protocol (n = 24), which was
randomly assigned by the statistician [11,12].
The mean age (SD) of the participants was 31.7 (±5.7)
years. In the GnRH-a long protocol group (n = 26), the
treatment started by administering oral contraception
pill (OCP) on the 2nd or the 3rd day of the pervious
menstrual cycle. The daily administration of Buserelin
acetate 500 μg (Suprefact, Aventis, Germany) was started
preceding the IVF cycle from day 21 until pituitary
down-regulation (serum E2 < 50 pg/ml in the absence of
follicular structures larger than 10 mm). The Buserelin
dose was reduced to 250 μg/d until the day of human
chorionic gonadotropin (hCG) injection when pituitary
down-regulation was achieved.
In the GnRH-ant fixed multi-dose protocol group
(n = 24), Cetrorelix acetate 0.25 mg/day (Cetrotide,
Serono, Switzerland) was initiated on the sixth day of
the gonadotropin stimulation.
Ovarian stimulation was started on the 3rd day of the
current menstrual cycle by injection of rFSH Follitropin
alfa (Gonal F, Serono, Italy) at a daily dose of 150 to
225 IU in each group.
Administration of Buserelin and Cetrorelix was con-
tinued until hCG was injected. When at least 3 follicles
with a mean diameter of 17 mm were developed (evalu-
ated by transvaginal sonography), hCG 5000 IU/2/IM
(Choriomon, IBSA Institut Biochimique S.A., Switzerland)
was injected. About 34–36 h later, ultrasound-guided
transvaginal oocyte retrieval was performed [13]. One
hundred morphologically normal germinal vesicle oocytes
were donated by 50 healthy women with normal ovarian
reserve functions. The oocytes were aspirated transvagin-
ally after COS. All the women had mature oocytes for
ICSI, but they donated immature ones to our study. We
obtained 50 germinal vesicle oocytes from 26 women aged
30.4 ± 5.5 years in the GnRH-a long protocol group and
50 germinal vesicle oocytes from 24 women aged 33.8 ±
5.6 years in the GnRH-ant protocol group. The oocytes
were collected in a Quinn’s Advantage Medium with
HEPES (Sage, USA) supplemented with 20 % human
serum albumin and then granulosa cells were removed
from oocytes using mechanical and chemical (Hyaluroni-
dase type 4, Sigma Aldrich, USA) methods.
After stripping off granulosa cells, we used an inverted
microscope (Nikon, Tokyo, Japan) to monitor the matur-
ity of the oocytes.
In the COS cycles, immature oocytes constitute up to
10-15 % of the retrieved oocytes. Germinal vesicle (GV)
oocytes are immature oocytes whose maturation process
have been stopped in the prophase of the first meioticstage and are characterized by enlarged nucleus and ab-
sent of polar body. Germinal vesicle oocytes were indi-
vidually transferred into RNase-free micro centrifuge
tubes. Then, 30 μl of RLT buffer (Ambion, Austin, USA)
was added to them. All samples were kept in a refriger-
ator at a temperature of −80°C until the time of the ana-
lysis. After the sampling, the pools of 50 germinal vesicle
oocytes from the GnRH-a long protocol group and 50
germinal vesicle oocytes from the GnRH-ant protocol
group were separately analyzed by qPCR.
RNA isolation, cDNA production and qPCR
ALLELEID 6.0 software was used for designing Exon-
Junction primers. Molecular evolutionary genetics ana-
lysis (MEGA 4) software was also used for conducting
sequence alignment. Oligo 6 Software was employed for
the final assessment (Temperature/ Formation/False prim-
ing sites). Finally, we assessed primers in NCBI BLAST, as
presented in Table 1.
Before isolating the RNA, the germinal vesicle oocytes
were thawed within RLT buffer at room temperature
and then pooled. To separate the RTL buffer from the
pooled oocytes, they were then centrifuged at 12000 g
for 3 minutes in order to extract total RNA, based on
the standard protocol suggested by the manufacturer
(Trizol, Invitrogen, USA). In order to remove genomic
DNA contamination from the samples, the total RNA
obtained from both groups was treated with DNase I
(Fermentas, Sanktleon-rot, Germany). The total RNA
concentration of the pooled germinal vesicle oocytes
after treatment was 594 μg/ml for the GnRH-a long
protocol group and 672 μg/ml for the GnRH-ant protocol
group, determined by a Thermo Scientific Nano Drop
2000 Spectrophotometer. cDNA was synthesized accord-
ing to manufacturer's instructions (Fermentas, Sanktleon-
rot, Germany) using random hexamer primers.
We performed qPCR on the cDNA obtained from the
pooled of germinal vesicle oocytes. Relative gene expres-
sion was calculated as the abundance ratio of each target
gene to β-actin.
Quantitative real time PCR reactions were conducted
in duplicates using a Roto- Gene Q instrument (Qiagen,
German) with SYBR® Premix Ex Taq™ II master mix ac-
cording to the procedure suggested by the manufactur-
er's instructions (Takara, Japan). The protocol for qPCR
was initiated with a denaturizing step at 95°C for 30 sec-
onds, followed by 50 cycles of 2-step, real-time PCR
under the following conditions: 5 seconds at 95°C for
denaturation and 30 seconds at 59–60°C for annealing
and extension.
No template control (NTC) was used as the negative
control. The specificity of the PCR fragments was deter-
mined using melting curve analysis. All melting curves
produced one peak for each of the PCR products.
Table 1 Oligonucleotide primer sequences used for qPCR in the present study
Gene name Primer Accession no. T°C Product size (bp)
GDF9 NM_005260.4 60 162
Sense CCAGGTAACAGGAATCCTTC
Antisense GGCTCCTTTATCATTAGATTG
BMP15 NM_005448.2 60 129
Sense CCTCACAGAGGTATCTGGC
Antisense GGAGAGATTGAAGCGAGTTAG
ATPase 6 YP_003024031.1 60 123
Sense CTGTTCGCTTCATTCATTG
Antisense GGTGGTGATTAGTCGGTTG
NAIP NM_004536.2 60 184
Sense GGAGTATTTGGATGACAGAAAC
Antisense TAGATTACCACTGGAGTCTTCC
BUB1 NM_001278616.1 59 100
Sense AAGGTCCGAGGTTAATCC
Antisense CACTGGTGTCTGCTGATAGG
MADL2 NM_002358.3 60 169
Sense CTTCTCATTCGGCATCAAC
Antisense ACACTTGTATAACCAATCTTTCAG
CDC20 NM_001255.2 60 202
Sense GATGTAGAGGAAGCCAAGATC
Antisense CCACAAGGTTCAGGTAATAGTC
ATR NM_001184.3 60 150
Sense GATGCCACTGCTTGTTATG
Antisense CCACTCGGACCTGTTAGC
ATM NM_000051.3 60 107
Sense GCATTACGGGTGTTGAAG
Antisense ATATAGAAGGACCTCTACAATG
β.actin NM_001101.3 60 90
Sense CAAGATCATTGCTCCTCCTG
Antisense ATCCACATCTGCTGGAAGG
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The present study was approved by the ethics committee
of Tehran University of Medical Sciences. The study was
completely explained to the women, and informed con-
sent was obtained before collecting germinal vesicles oo-
cytes. The study was formally registered with the
following code: IRCT 2014031112307 N3.
Statistical analysis
We used One-way ANOVA to compare quantitative var-
iables between the two groups and chi-square for quali-
tative variables by SPSS version 16 (Chicago, IL, USA).
The significance level was set at 0.05. The efficiency
values given by the Linreg software and relative expres-
sion were calculated using the REST 2009 software
(Qiagen, Hilden, Germany) [14], which is a standalonesoftware tool used for estimating up and down regula-
tion for gene expression studies. The ΔΔCT was ob-
tained by finding the difference between the groups.
The fold change was calculated as FC = 2-ΔΔCT. For
this purpose, β.actin was used as the reference gene for
expression normalization.
Results
There were no significant differences in the age, hormo-
nal profile, number of oocytes retrieved, infertility dur-
ation, and cause of infertility between the two groups
(P > 0.05). However, the serum level of 17-beta estra-
diol on the day of hCG administration was higher in
the GnRH-ant protocol group than in the GnRH-a
long protocol group; however, this difference was not
statistically significant, as presented in Tables 2 and 3.
Table 2 Mean (standard deviation) age, duration of infertility, number of oocytes retrieved, serum LH, FSH, TSH, PRL,
AMH, and serum 17-beta estradiol in the GnRH-a protocol vs. GnRH-ant protocol group
Variable GnRH-a long protocol (n = 26) GnRH-ant protocol (n = 24) Total (n=50) P value
Age (yrs) 30.4 ± 5.5 33.8 ± 5.6 31.7 ± 5.7 0.100
Duration of infertility (yrs) 6.8 ± 3.5 4.6 ± 5.1 5.8 ± 4.5 0.086
Retrieved oocytes no. 11.0 ± 5.8 12.8 ± 8.3 11.8 ± 7.1 0.372
MII 6.2 ± 6.2 8.3 ± 6.3 7.2 ± 7.2 0.157
MI 1.8 ± 1.7 1.5 ± 1.6 1.6 ± 1.7 0.579
GV 2.1 ± 1.8 2.3 ± 1.8 2.2 ± 1.8 0.671
Deg. 0.8 ± 2.1 0.6 ± 2.1 0.7 ± 2.0 0.762
Serum 17 beta-estradiol (Pg/ml)* 5007.9 ± 8105 5988.3 ± 8110.6 5478.5 ± 8040.8 0.671
Serum LH (IU/L) 6.5 ± 2.9 5.5 ± 2.5 6.0 ± 2.8 0.256
Serum FSH (IU/L) 6.5 ± 2.5 6.3 ± 2.2 6.4 ± 2 0.706
Serum TSH (μIU/L) 3.0 ± 2.1 2.4 ± 1.1 2.7 ± 1.7 0.213
Serum PRL (ng/ml) 113.3 ± 186.2 107.0 ± 173.0 110.0 ± 178.2 0.902
Serum AMH (ng/ml) 5.0 ± 4.8 5.9 ± 5.6 5.4 ± 5.2 0.535
*On the day of hCG administration.
LH: luteinising hormone; FSH: follicle-stimulating hormone; TSH: thyroid-stimulating hormone; PRL: prolactin; AMH: anti-mullerian hormone.
MII: mature oocyte (Meiosis II); MI: immature oocyte (Meiosis I); GV: immature oocyte (Germinal Vesicle); Deg.: degenerative oocyte.
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genes involved in the cytoplasmic maturity (BMP15 and
GDF9), antiapoptotic process (NAIP), and adenosine tri-
phosphate production (ATPase 6) in human GV oocytes
were significantly higher in the GnRH-ant group versus
in the GnRH-a group. ATPase 6, BMP15, and NAIP
were significantly upregulated in the GnRH-ant group
compared to the GnRH-a group with the fold change of
3.990 (SD ± 1.325), 6.274 (SD ± 1.542), and 2.156 (SD ±
1.443), respectively, (P value < 0.001). GDF9 mRNA did
not have any expression in the GnRH-a group; however,
GDF9 mRNA was expressed in the GnRH-ant group.
These results are shown in Figure 1.
Finally, it was found that the genes involved in the
DNA repairing, i.e. Ataxia telangiectasia and Rad3-
related protein (ATR), and Ataxia telangiectasia mutated
(ATM); and those involved in the cell cycle checkpoint, i.
e. Bone morphogenetic protein 15 (BUB1), Mitotic arrest
deficient-like 1 (MAD2L1), and Cell division cycle 20
(CDC20), did not have any expression in either group, as
presented in Table 4.Table 3 Distribution of the causes of infertility in the
GnRH-a protocol vs. GnRH-ant protocol group
Variable GnRH-a (%) GnRH-ant (%) P value
Cause of infertility
● Male factor 16 (61.5) 9 (37.5)
● Tubal factor 8 (30.8) 11 (45.58)
● Unexplained 2 (7.7) 4 (16.7)
Total 26.0 (100.0) 24.0 (100.0) 0.220Discussion
Clinical studies have suggested similar pregnancy and
live birth rates for both GnRH-a and GnRH-ant proto-
cols [1,3,15-21], which has been further supported by
some molecular studies [6-9]. Additionally, no signifi-
cant morphological difference has been observed in the
oocytes of the two groups after COS [22].
However, several advantages have been observed for
the GnRH-ant protocol, including the fact that under
this protocol, the endometrial receptivity is more similar
to the natural cycle receptivity (in terms of endometrial
chemokines and growth factors) [23]. In addition, whenFigure 1 Results of the gene expression analysis with REST
when using β.actin as the reference gene. Fold change (Y axis)
represents the relative expression of ATPase 6, BMP15, NAIP mRNA in
the pooled GV oocytes of the GnRH-ant protocol group (as tested
group) versus the pooled GV oocytes of the GnRH-a long protocol
group (as control group). ATPase 6, BMP15, and NAIP significantly
were upregulated in GnRH-ant group in compared to GnRH-a group
with the fold change of 3.990 (SD ± 1.325), 6.274 (SD ± 1.542), and
2.156 (SD ± 1.443), respectively, *** P < 0.001. Agonist protocol
group □. Antagonist protocol group ■.
Table 4 The genes expression of germinal vesicle oocyte in GnRH agonist group compared with GnRH antagonist
group
Gene symbol Gene title GnRH-a group GnRH-anta group
Exist Not exist Exist Not exist
Transforming growth factors
GDF9 Growth differentiation factor 9 + +
BMP15 Bone morphogenetic protein 15 + +
Mitochondria
ATPase6 Adenosine triphosphatase 6 + +
Antiapoptotic
NAIP Neuronal apoptosis inhibitory protein + +
Cell cycle checkpoint markers
BUB1 Budding uninhibited by benzimidazoles 1 + +
MAD2L1 Mitotic arrest deficient-like 1 + +
CDC20 Cell division cycle 20 + +
DNA repair markers
ATR Ataxia telangiectasia and Rad3 + +
ATM Ataxia telangiectasia mutated + +
Reference gene
B.actin beta actin + +
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cols, the time of the appearance of the endometrial triple
layer is statistically significant for the pregnancy rate
only for the former protocol [24]. In addition to its
safety and effectiveness, GnRH-ant allows for the flexi-
bility of treatment in a wider range of women popula-
tions, including poor responders, women undergoing
first-line controlled ovarian stimulation, and women di-
agnosed with polycystic ovarian syndrome. Therefore,
the GnRH-ant protocol can be considered as a suitable
alternative to the long agonist protocol, due mainly to
its shorter duration of treatment and the need for fewer
injections. Consequently, this leads to a significantly
lower amount of administered gonadotropins, which
most probably leads to improved women compliance
[25]. We observed, for the first time, that the expression
levels of genes involved in the cytoplasmic maturity,
antiapoptotic process, and ATP production in human
GV oocytes were significantly higher in the GnRH-anta
group than in the GnRH-a group in COS.
As with other studies, in the present work, the same
ovulation-triggering drug was used in the COS cycle for
both groups; the only difference was the type of GnRH
used for the two groups, which makes the present work
different from the study of Hass et al. [26], in which oo-
cyte cells were used for genetic evaluations.
The present study showed that the expression levels of
genes involved in the cytoplasmic maturity, antiapopto-
tic process, and adenosine triphosphate production were
significantly higher in the pooled oocytes of the womenin the GnRH antagonist group versus those of the
women in the GnRH agonist group (P < 0.001). These
results are shown in Figure 1.
ATPase 6 gene plays a critical role in ATP production by
mitochondria. Deficiencies in the production of mitochon-
drial ATP can be linked to impaired oocyte fertilization,
incomplete development of the embryo at later stages,
and several other cellular and chromosomal disorders in-
cluding errors in chromosomal segregation, lethal cyto-
plasmic defects, non disjunction disorders resulting in
aneuploidy, and development failure of the sperm derived
mitotic apparatus [27]. Therefore, the higher expression
level of ATPase6 in the pooled oocytes of the women in
the GnRH-ant protocol group vs. those of the women in
the GnRH-a long protocol group suggests that under the
antagonist protocol, the mitochondrial activity may be
more appropriate. In other words, higher-quality mito-
chondrial respiration and oxidative phosphorylation cas-
cade occur in the oocytes of GnRH-ant group. The higher
expression level of this gene and, in turn, higher energy
production cause cell division spindles to form under bet-
ter conditions [27].
Transforming growth factors beta (TGF-ß) are import-
ant paracrine growth factors that are secreted by the
ovarian stroma or follicles surrounding the ovary, con-
verting primordial follicles to primary ones. During folli-
culogenesis stages, oocytes secretion of TGF-ß, such as
BMP15 and GDF9 [28], can regulate female fertility in
several mammals [5,29,30]. GDF9 and BMP15 are respon-
sible for transformation. They also cause the reproduction
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mainly secrete estradiol [35]. Estradiol is required for the
maturation of oocytes and development of embryo
in vivo. Additionally, follicular atresia and granulosa
cell apoptosis are inhibited by GDF9. Moreover, the
proliferation, apoptosis, metabolism, and expansion of
the cumulus oocyte complex are organized by the se-
cretion of GDF9 and BMP15 [29].
According to the results from the present study, GDF9
and BMP15 are expressed in the pooled GV oocytes of
the women in the GnRH-ant protocol group. Our study
also showed that the expression level of GDF9 was
higher than that of BMP15 in the antagonist group,
which is consistent with the results of previous studies
[30]. GDF9 gene was not expressed in the pooled GV
oocytes of the women in the GnRH-a long protocol
group. The higher expression of these genes in the
pooled GV oocytes of the GnRH-ant protocol group
could be due to the fact that in the GnRH-a long proto-
col, complete inhibition of gonadotropins occurs on the
2nd or the 3rd day of the current menstrual cycle. The
study of Lainas et al. [36] indicated that the serum levels
of E2, FSH, and LH hormones were significantly higher
before administering OCP on the 2nd or the 3rd day of
the pervious menstrual cycle when compared to the
same day in the OCP plus GnRH-a long protocol,
mainly due to the suppression of inner gonadotropin in
this protocol (FSH: 5.8 vs. 3.6 IU/L; LH:5.6 vs. 1.2 IU/L;
and E2: 30.5 vs. 12 pg/ml before and after using OCP/
GnRH-a, respectively). This, however, does not occur in
the GnRH-ant protocol. In the GnRH-ant protocol, the
initial dose of GnRH-ant is administered on the 6th or
the 7th day of the current menstrual cycle, which causes
immediate inhibition of LH by influencing the GnRH re-
ceptors in the pituitary gland. Therefore, adequate fol-
licle stimulation can be provided by a combination of
exogenous FSH and endogenous LH secretion in early
treatment [37]. In other words, administration of GnRH-
ant protocol occurs in late follicular development (on
the 5th or the 6th day of the gonadotropin stimulation
when estradiol is increased).
NAIP is one of the members of the inhibitor of apop-
tosis protein (IAP) family. By regulating the caspase ac-
tivity (inhibition of both caspase 3 and caspase 9), which
is an important part of the apoptotic machinery, this
gene can prevent apoptosis of granulosa cells during the
ovarian folliculogenesis stages and can cause the follicles
to develop from the primary stage to the graafian follicle
[32]. In the oocyte, the expression of this gene can in-
crease 2–4 times due to the effect of gonadotropin,
which indirectly leads to oocyte survival [33,34]. After a
thorough literature search, it was determined that the
present study examined, for the first time, the expression
level of NAIP in human oocytes. The higher level of theexpression of this gene in the pooled oocytes in the
GnRH-ant protocol versus the pooled oocytes in the
GnRH-a long protocol most likely suggests that the
oocyte survival is improved by applying the former
protocol.
In addition, in the present study, BUB1, MAD2L1,
CDC20, ATR, and ATM genes did not have any expres-
sion in either group, which is most likely because that
the oocytes used in the present work were germinal
vesicle oocytes whose growth is arrested in the diplotene
stage of the first meiotic prophase, as presented in Table 4.
ATR and ATM are a type of serine/threonine protein
kinase. DNA double-strand breaks recruit and activate
this serine/threonine protein kinase. This leads to the
phosphorylation of several key proteins that are respon-
sible for the initiation of DNA damage checkpoint acti-
vation, which finally results in cell cycle arrest, DNA
repair, or apoptosis. ATM and ATR prevent premature
chromosome condensation (PCC) until the DNA repli-
cation is completed [31].
In order to prevent premature separation of sister
chromatids, MAD2L1 and BUB1, which in turn interact
with CDC20 at check point activation, inhibit CDC20/
APC [10]. Previous studies indicated that during the
meiosis, BUB1, MAD2L1, and CDC20 had high expres-
sions in the oocytes [28].
There are controversial findings regarding the differ-
ence in the serum levels of estradiol on the day of hCG
administration between GnRH-ant and GnRH-a long
protocols. Some studies have reported that the serum
levels of estradiol on the day of hCG administration are
significantly higher in the GnRH-a long protocol than in
the GnRH-ant protocol [38]; other studies, however,
have reported reverse findings [21,39-41]. In the present
study, the serum levels of estradiol on the day of hCG
administration were higher in the GnRH-ant protocol
than the GnRH-a long protocol although the difference
was not statistically significant, as presented in Tables 2.
The serum level of estradiol is an indicator of the func-
tion of granulosa cells, suggesting that these cells have
better performance in producing estradiol in the GnRH-
ant protocol versus the GnRH-a long protocol.
Studies have indicated that the application of GnRH
agonist protocol causes mid-cycle gonadotropine flares
and ovarian hyperstimulation syndrome (OHSS), which
is more observed in women with poly-cystic ovarian syn-
drome (PCOs). Therefore, the GnRH-ant protocol is a
better choice than the GnRH-a protocol for ovarian
stimulation in infertile women due to PCOs [1,4,25].
On the other hand, Li et al. [30] reported that the ex-
pression of GDF9 and BMP15 genes is necessary for the
maturity of the oocyte cytoplasm; therefore, these two
can be used as markers of oocyte quality in terms of its
evolution. In addition, it was reported that in the oocytes
Hoseini et al. DARU Journal of Pharmaceutical Sciences 2014, 22:67 Page 8 of 9
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GDF9 and BMP15 genes is lower than that of normal in-
dividuals, which can be the reason for the lowered qual-
ity of oocytes in these patients, which in turn leads to
reduced fertility and the rate of success in IVF.
Therefore, since the results from the present study
suggested higher expression level of these genes when
GnRH-ant protocol is applied [Figure 1], this protocol
seems to be a more appropriate choice for women with
PCOs, because it can probably improve the expression
of the aforementioned genes.
Although similar studies should be performed on the
matured oocytes, but obtaining of donated mature oocytes
(in vivo) is not ethically feasible for research purposes. On
the other hand, the mature oocytes obtained from GV
in vitro maturation is not appropriate for this purpose,
mainly because studies have indicated that the in vitro
culture conditions have adverse genetic and epigenetic
impact on the growth of GV oocytes; therefore, this
can prevent the researchers from observing the same
findings. We suggest that future studies should be per-
formed on donated mature oocytes which, together
with the results of the present work, can help provide
a broader molecular perspective in this field and make
the most appropriate ovarian stimulation protocol.Conclusions
Results from the present study indicated, for the first
time, that in the germinal vesicle oocytes of women with
normal ovarian function, the expression levels of genes
involved in the cytoplasmic maturity (GDF9 and BMP15),
antiapoptotic process (NAIP), and ATP production (ATPase
6) were significantly higher in the GnRH-anta protocol
group than in the GnRH-a long protocol group. GDF9
mRNA did not have any expression in the GnRH-a group;
however, GDF9 mRNA was expressed in the GnRH-ant
group. Therefore, since the results from the present study
suggested higher expression level of these genes when
GnRH-ant protocol is applied, this protocol seems to be a
more appropriate choice for women with PCOs, because it
can probably improve the expression of the aforementioned
genes.
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